We have acquired exclusive rights to commercialise an investigational oral therapy for early-stage Alzheimer’s disease in our key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries.
Leadership announcements and new Arcera structure
We form partnerships to develop, manufacture, market, and distribute medicines, ensuring that patients receive the treatment they need.
Report underscores Acino’s continued commitment to Environmental, Social, and Governance goals, including a firm commitment to reaching full carbon neutrality by 2050.
Following the acquisition of M8 Pharmaceuticals, Acino is combining its Latin America business units to drive pharmaceutical growth and innovation in the region and beyond.
Established in Switzerland since 1836 and with a proven track record of high quality products for many years the deeply rooted high standard quality pledge is reflected in all of Acino’s activities.
When you choose Acino, you are choosing quality you can rely on.
We have a bold ambition and actively pursue excellence in all we do.
Who we are, what we stand for and are signposts for what we need to aspire to in our everyday actions.
We use cookies to create statistics that help us to improve the quality of our website and your user experience. By clicking on “Accept All”, you consent to the processing of data by Acino and the transfer of data to third parties. You can also tailor your consent for specific data processing purposes. Once you have made your choice, click on “Confirm”. Find detailed information and modify your preferences at any time in our Privacy Notice.
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
We would like to set Google Analytics cookies to help us analyse the traffic on our website.